Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry)
Launched by FEDERICO II UNIVERSITY · Mar 6, 2021
Trial Information
Current as of May 02, 2025
Recruiting
Keywords
ClinConnect Summary
The POMPEII Registry is a clinical trial that is looking into how a medication called cangrelor affects patients who are undergoing a procedure known as percutaneous coronary intervention (PCI). This procedure is often done to treat blocked arteries in the heart. The study aims to understand how cangrelor works in these patients, helping doctors ensure they use the best treatments possible.
If you are an adult patient who will be receiving cangrelor during a PCI, you may be eligible to participate in this trial. The main requirement is that you are willing to give consent for blood and data collection. As a participant, you can expect to contribute to important research that can help improve care for future patients undergoing similar procedures. Remember, your involvement is voluntary, and you can ask questions or withdraw from the study at any time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All adult patients undergoing PCI and receiving cangrelor administration will be eligible for inclusion in the study.
- Exclusion Criteria:
- • only those not providing consent to blood/data collection will be excluded.
About Federico Ii University
Federico II University, located in Naples, Italy, is a prestigious academic institution with a strong emphasis on advanced research and clinical innovation. As a clinical trial sponsor, the university is committed to fostering the development of novel therapeutic interventions and enhancing patient care through rigorous scientific inquiry. With a multidisciplinary approach, Federico II University collaborates with healthcare professionals, researchers, and industry partners to conduct high-quality clinical trials that adhere to ethical standards and regulatory requirements. Its dedication to improving health outcomes is reflected in its robust research programs and commitment to translating scientific findings into clinical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Napoli, , Italy
Patients applied
Trial Officials
Giuseppe Gargiulo, MD, PhD
Principal Investigator
Department of Advanced Biomedical Sciences, University Federico II of Naples, Italy
Giovanni Esposito, MD, PhD
Study Chair
Department of Advanced Biomedical Sciences, University Federico II of Naples, Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials